Today, the H. Lee Moffitt Cancer Center & Research Institute (Moffitt) was accredited with the CEO Cancer Gold Standard(TM) certification, recognizing the organization’s commitment to the health of their employees and family members by certifying their efforts to meet an exceptionally high standard of cancer prevention, screening and care guidelines. In doing so, Moffitt joins with twenty-one other organizations that have demonstrated exemplary effort to prevent cancer in the workplace and in their leadership in the overall fight against cancer.
William C. Weldon, chairman and chief executive officer of Johnson & Johnson chairs the CEO Roundtable on Cancer, the nonprofit organization of cancer-fighting CEOs that created the CEO Cancer Gold Standard(TM), in collaboration with the American Cancer Society, NCI-designated comprehensive cancer centers and leading corporate health professionals.
“The commitment of Moffitt and other NCI-designated cancer centers to patient care and cutting edge cancer research is well documented and the accolades are well deserved,” said Weldon. “This CEO Cancer Gold Standard certification further acknowledges that under the leadership of the Honorable H. Lee Moffitt and CEO, Dr. William C. Dalton, their commitment to the health and well-being of their employees is also unparalleled.”
The CEO Cancer Gold Standard(TM), calls for companies to evaluate their benefits and culture and take extensive, concrete actions in five key areas of health and wellness to fight cancer in the workplace. To earn Gold Standard accreditation, a company must establish programs to reduce cancer risk by discouraging tobacco use and encouraging physical activity, healthy diet and nutrition; detect cancer at its earliest stages; and provide access to quality care, including the availability of clinical trials.
The most recent President’s Cancer Panel report, “Promoting Healthy Lifestyles: Policy, Program, and Personal Recommendations for Reducing Cancer Risk,” identified the CEO Cancer Gold Standard(TM) as an initiative that is helping reverse negative, unhealthy lifestyle trends and creating hope in the fight against cancer for America’s workers and their families.
Joining Moffitt in this workplace-based effort to eliminate cancer as a public health threat are: American Cancer Society, American Legacy Foundation, AstraZeneca, C-Change, Duke Medicine, Edelman, Enzon Pharmaceuticals, GHI, GlaxoSmithKline, Jenner & Block, Johnson & Johnson, The Lance Armstrong Foundation, MD Anderson Cancer Center, Novartis, OSI Pharmaceuticals, PhRMA, PPD, Quintiles Transnational, SAS Institute, The University of North Dakota and Valeant Pharmaceuticals.
About H. Lee Moffitt Cancer Center & Research Institute
Located in Tampa, Florida, Moffitt Cancer Center is the only Florida-based cancer center with the NCI designation as a Comprehensive Cancer Center for its excellence in research and contributions to clinical trials, prevention and cancer control. Moffitt currently has 15 affiliates in Florida, one in Georgia and two in Puerto Rico. Additionally, Moffitt is a member of the National Comprehensive Cancer Network, a prestigious alliance of the country’s leading cancer centers, and is listed in U.S. News & World Report as one of America’s Best Hospitals for cancer. Moffitt’s sole mission is to contribute to the prevention and cure of cancer.
About the CEO Roundtable on Cancer
The CEO Roundtable on Cancer was founded in 2001, when former President George H.W. Bush challenged a group of executives to “do something bold and venturesome about cancer within your own corporate families.” The CEOs responded with the CEO Cancer Gold Standard encouraging its widespread adoption in workplaces across the country. For more information on the CEO Cancer Gold Standard(TM) and the accreditation process, please visit www.CancerGoldStandard.org.
(Due to the length of the URL in the following contact information, it may be necessary to copy and paste this hyperlink into your Internet browser’s URL address field. Remove the extra space if one exists.)
Comments